Omnicell Free Cash Flow 2010-2024 | OMCL
Omnicell free cash flow from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Omnicell Annual Free Cash Flow | |
|---|---|
| 2023 | 139.62 |
| 2022 | 30.25 |
| 2021 | 202.84 |
| 2020 | 163.03 |
| 2019 | 129.11 |
| 2018 | 80.27 |
| 2017 | 9.49 |
| 2016 | 36.46 |
| 2015 | 30.94 |
| 2014 | 53.24 |
| 2013 | 42.93 |
| 2012 | 24.36 |
| 2011 | 22.56 |
| 2010 | 13.71 |
| 2009 | 42.63 |
| Omnicell Quarterly Free Cash Flow | |
|---|---|
| 2024-03-31 | 41.00 |
| 2023-12-31 | 139.62 |
| 2023-09-30 | 110.28 |
| 2023-06-30 | 63.90 |
| 2023-03-31 | 2.63 |
| 2022-12-31 | 30.25 |
| 2022-09-30 | -38.23 |
| 2022-06-30 | -46.65 |
| 2022-03-31 | -27.49 |
| 2021-12-31 | 202.84 |
| 2021-09-30 | 154.29 |
| 2021-06-30 | 118.12 |
| 2021-03-31 | 52.33 |
| 2020-12-31 | 163.03 |
| 2020-09-30 | 92.16 |
| 2020-06-30 | 59.52 |
| 2020-03-31 | 22.06 |
| 2019-12-31 | 129.11 |
| 2019-09-30 | 97.56 |
| 2019-06-30 | 44.39 |
| 2019-03-31 | 21.52 |
| 2018-12-31 | 80.27 |
| 2018-09-30 | 37.26 |
| 2018-06-30 | 25.74 |
| 2018-03-31 | 9.59 |
| 2017-12-31 | 9.49 |
| 2017-09-30 | 11.27 |
| 2017-06-30 | 32.43 |
| 2017-03-31 | 25.73 |
| 2016-12-31 | 36.46 |
| 2016-09-30 | 16.03 |
| 2016-06-30 | 10.95 |
| 2016-03-31 | 17.75 |
| 2015-12-31 | 30.94 |
| 2015-09-30 | -0.15 |
| 2015-06-30 | 6.43 |
| 2015-03-31 | 10.27 |
| 2014-12-31 | 53.24 |
| 2014-09-30 | 24.16 |
| 2014-06-30 | 18.09 |
| 2014-03-31 | -1.43 |
| 2013-12-31 | 42.93 |
| 2013-09-30 | 32.92 |
| 2013-06-30 | 15.52 |
| 2013-03-31 | 0.83 |
| 2012-12-31 | 24.36 |
| 2012-09-30 | 17.92 |
| 2012-06-30 | 14.67 |
| 2012-03-31 | 5.85 |
| 2011-12-31 | 22.56 |
| 2011-09-30 | 7.82 |
| 2011-06-30 | 2.50 |
| 2011-03-31 | 0.69 |
| 2010-12-31 | 13.71 |
| 2010-09-30 | 5.81 |
| 2010-06-30 | 10.21 |
| 2010-03-31 | 7.05 |
| 2009-12-31 | 42.63 |
| 2009-09-30 | 22.25 |
| 2009-06-30 | 4.30 |
| 2009-03-31 | -3.27 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $1.398B | $1.147B |
| Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application. The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs. The company also adheres to regulatory compliances and addresses issues related to population health. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GE HealthCare Technologies (GEHC) | United States | $37.366B | 20.52 |
| Inspire Medical Systems (INSP) | United States | $4.612B | 0.00 |
| Axonics (AXNX) | United States | $3.446B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $3.129B | 0.00 |
| 10x Genomics (TXG) | United States | $2.980B | 0.00 |
| Olink Holding AB (publ) (OLK) | Sweden | $2.978B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $2.950B | 0.00 |
| Enovis (ENOV) | United States | $2.875B | 21.30 |
| Azenta (AZTA) | United States | $2.743B | 154.15 |
| Privia Health (PRVA) | United States | $2.016B | 112.67 |
| Schrodinger (SDGR) | United States | $1.654B | 0.00 |
| Phreesia (PHR) | United States | $1.393B | 0.00 |
| Standard BioTools (LAB) | United States | $0.746B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.662B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.649B | 0.00 |
| Talkspace (TALK) | United States | $0.467B | 0.00 |
| Clover Health Investments (CLOV) | United States | $0.442B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.410B | 0.00 |
| Pulmonx (LUNG) | United States | $0.349B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.296B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.217B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.191B | 0.00 |
| Outset Medical (OM) | United States | $0.187B | 0.00 |
| American Well (AMWL) | United States | $0.145B | 0.00 |
| TruBridge (TBRG) | United States | $0.134B | 7.19 |
| 111 (YI) | China | $0.111B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.107B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.075B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.070B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.064B | 0.00 |
| Augmedix (AUGX) | United States | $0.059B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.057B | 0.00 |
| HeartBeam (BEAT) | United States | $0.055B | 0.00 |
| Zepp Health (ZEPP) | China | $0.054B | 0.00 |
| CareCloud (CCLD) | United States | $0.045B | 0.00 |
| Movano (MOVE) | United States | $0.042B | 0.00 |
| Akili (AKLI) | United States | $0.034B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.031B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.022B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.020B | 0.00 |
| Cue Health (HLTH) | United States | $0.015B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.014B | 0.00 |
| Syra Health (SYRA) | United States | $0.010B | 0.00 |
| Biotricity (BTCY) | United States | $0.010B | 0.00 |
| Transgenomic (PRPO) | United States | $0.009B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.007B | 0.00 |
| HeartSciences (HSCS) | United States | $0.005B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.004B | 0.00 |
| Zhongchao (ZCMD) | China | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.001B | 0.00 |
| Centogene (CNTG) | Germany | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |